Submit or Track your Manuscript LOG-IN

Low Dose of Azithromycin Enhances the Anticancer Efficacy of Sorafenib in HepG2 Cell Line

Low Dose of Azithromycin Enhances the Anticancer Efficacy of Sorafenib in HepG2 Cell Line

Dabeeran Zehra1, Zahida Memon1, Shumaila Usman2,*, Almas Jabeen3, Kauser Ismail1 and Rehan Ahmed Siddiqui2

1Department of Pharmacology, Ziauddin University, Karachi
2Department of Research, Ziauddin University, Karachi
3Dr. Panjwani Centre for Molecular Medicine and Drug research, International Centre for Chemical and Biological Sciences, Karachi
 
* Corresponding author: shumaila.usman@zu.edu.pk

ABSTRACT

Sorafenib, a multi kinase inhibitor, is the only FDA approved drug designed to target advanced hepatocellular carcinoma (HCC). However, unbearable side effects, insufficient efficacy and resistance mechanisms against this drug, generates necessity to develop novel therapeutic strategies and drugs. Recently macrolides have drawn attention of researchers in the treatment of cancer owing to their proposed chemotherapeutic role, based on the concept of repurposing, as they are well tolerated, less toxic and inexpensive. In this study we evaluated the combine effects of low dose of Azithromycin with Sorafenib in HepG2 cell line. Co-treatment of Sorafenib and Azithromycin showed enhanced inhibition of cell growth and suppressed the MAPK pathway associated with cellular proliferation, however the effects on cellular apoptosis were found to be insignificant.

 

To share on other social networks, click on any share button. What are these?

Pakistan Journal of Zoology

August

Vol. 54, Iss. 4, Pages 1501-2001

Featuring

Click here for more

Subscribe Today

Receive free updates on new articles, opportunities and benefits


Subscribe Unsubscribe